BMY News | Bristol-Myers Squibb Co. Articles

Results 121 - 130 of 474 : Previous 9 10 11 12 13 14 15 16 17 Next

Investing | July 20, 2011

First in Class Isn't the Sweetest Position

Bristol and AzstraZeneca's diabetes drug dapagliflozin runs into trouble.

High-Growth Investing | July 18, 2011

The Tale of 2 Drug Handbacks

Bristol-Myers returns another drug to Exelixis.

Fierce Markets | July 16, 2011

FDA Cites Risks in Diabetes Drug

An experimental drug from AstraZeneca and Bristol-Myers Squibb is potentially linked to certain cancers.

Fierce Markets | July 14, 2011

Yervoy May Help BMS Survive European Squeeze

It's the first new treatment in decades.

Dividends & Income Investing | July 13, 2011

Roundtable: Best Dividends in Health Care

Hunting for more income? Look here.

Investing | July 13, 2011

One Biotech Stock to Avoid

Our investing community's latest pick to avoid: Vical.

High-Growth Investing | July 13, 2011

2 Questions for Seattle Genetics

Only two is a good sign.

Value Investing | July 08, 2011

Half a Breakup Is Better Than No Breakup at All

Pfizer keeps two divisions and puts two on the chopping block.

Value Investing | July 08, 2011

Is Forest Labs' Stock Cheap?

Let's take a look.

Value Investing | July 06, 2011

Don't just ask, "How much inventory?" Ask, "What kind?"

Results 121 - 130 of 474 : Previous 9 10 11 12 13 14 15 16 17 Next